Market News / Story
Glaukos slips as insider selling overshadows positive trial data for eye therapy
Seeking Alpha ·
Seeking Alpha reports: Despite announcing positive data from a late-stage trial for its Epioxa eye therapy, Glaukos Corporation lost more than 13% on Thursday amid an insider sale by the company’s chief development officer, Tomas Navratil. According to a regulatory filing on Tuesday, Navratil sold more than 1,500 shares of Glaukos in three different transactions at a range of $163.93-$165.60 on average, consistent with a 10b5-1 trading plan adopted on June 12. The transactions valued at…